These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. Agabiti Rosei E; Salvetti M High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901 [TBL] [Abstract][Full Text] [Related]
25. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Leipold R; Raal F; Ishak J; Hovingh K; Phillips H Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748 [TBL] [Abstract][Full Text] [Related]
26. Microsomal triglyceride transfer protein inhibition: a novel treatment for lowering plasma cholesterol. Das G; Rees A Curr Opin Lipidol; 2014 Dec; 25(6):471-3. PubMed ID: 25370457 [No Abstract] [Full Text] [Related]
27. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Cuchel M; Meagher EA; du Toit Theron H; Blom DJ; Marais AD; Hegele RA; Averna MR; Sirtori CR; Shah PK; Gaudet D; Stefanutti C; Vigna GB; Du Plessis AM; Propert KJ; Sasiela WJ; Bloedon LT; Rader DJ; Lancet; 2013 Jan; 381(9860):40-6. PubMed ID: 23122768 [TBL] [Abstract][Full Text] [Related]
29. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia. Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894 [TBL] [Abstract][Full Text] [Related]
30. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058 [TBL] [Abstract][Full Text] [Related]
31. Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review. Neef D; Berthold HK; Gouni-Berthold I Expert Rev Clin Pharmacol; 2016; 9(5):655-63. PubMed ID: 26943823 [TBL] [Abstract][Full Text] [Related]
32. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Perry CM Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215 [TBL] [Abstract][Full Text] [Related]
34. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
35. Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia. Harada-Shiba M; Koezuka R; Makino H; Ogura M J Atheroscler Thromb; 2023 Feb; 30(2):203-205. PubMed ID: 35732425 [No Abstract] [Full Text] [Related]
36. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder. Smith RJ; Hiatt WR JAMA Intern Med; 2013 Sep; 173(16):1491-2. PubMed ID: 23649296 [No Abstract] [Full Text] [Related]